When compared to controls, the CAM1615HER2 TriKE also showed increased CD107a and IFNγ NK cell activity against a broad panel of ovarian cancer cell lines including OVCAR3 (Figure 3C,D), OVCAR5 (Figure 3E,F), OVCAR8 (Supplementary Figure S3A,B), and OVCAR4 (Supplementary Figure S3C,D) cell lines. This evidence concerns the gene LAMP1 and ovarian carcinoma.